Establishment of human induced pluripotent stem cell line from a patient with Angelman syndrome carrying the deletion of maternal chromosome 15q11.2-q13.

Stem Cell Res

Center for iPS Cell Research and Application (CiRA), Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, Japan; iPSC-based Drug Discovery and Development Team, RIKEN BioResource Research Center, Kyoto, Japan. Electronic address:

Published: January 2019

Angelman syndrome is a rare neurodevelopmental disorder caused by the loss of function of the maternally expressed E3 ubiquitin ligase UBE3A. We established human induced pluripotent stem cells (iPSCs) from an Angelman syndrome patient with the deletion of maternal 15q11.2-q13 including UBE3A gene. The generated iPSC line showed pluripotency markers and the ability of in vitro differentiation into the three-germ layer. FISH analysis and methylation-specific PCR analysis of genomic DNA revealed the deletion of maternal 15q11.2-q13 in the iPSCs. This iPSC line will be useful for elucidating pathomechanisms and for drug discovery and development for Angelman syndrome.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.scr.2018.101363DOI Listing

Publication Analysis

Top Keywords

angelman syndrome
16
deletion maternal
12
human induced
8
induced pluripotent
8
pluripotent stem
8
maternal 15q112-q13
8
establishment human
4
stem cell
4
cell patient
4
angelman
4

Similar Publications

Lipid nanoparticles (LNPs) are the preeminent non-viral drug delivery vehicle for mRNA-based therapies. Immense effort has been placed on optimizing the ionizable lipid (IL) structure, which contains an amine core conjugated to lipid tails, as small molecular adjustments can result in substantial changes in the overall efficacy of the resulting LNPs. However, despite some advancements, a major barrier for LNP delivery is endosomal escape.

View Article and Find Full Text PDF

Baby Jack.

JAMA

January 2025

Miga Health, San Francisco, California.

View Article and Find Full Text PDF

Proteomic Profiling of Potential E6AP Substrates via Ubiquitin-based Photo-Crosslinking Assisted Affinity Enrichment.

Chembiochem

January 2025

Departments of Biology and Chemistry, Konstanz Research School Chemical Biology, University of Konstanz, Universitätsstraße 10, 78467, Konstanz, Germany.

The ubiquitin (Ub) ligase E6AP, encoded by the UBE3A gene, has been causally associated with human diseases including cervical cancer and Angelman syndrome, a neurodevelopmental disorder. Yet, our knowledge about disease-relevant substrates of E6AP is still limited, presumably because at least some of these interactions are rather transient, a phenomenon observed for many enzyme-substrate interactions. Here, we introduce a novel approach to trap such potential transient interactions by combining a stable E6AP-Ub conjugate mimicking the active state of this enzyme with photo-crosslinking (PCL) followed by affinity enrichment coupled to mass spectrometry (AE-MS).

View Article and Find Full Text PDF

Gait disturbance is a common motor symptom in Angelman syndrome (AS), but its characteristics have been poorly studied quantitatively. This study aimed to analyze gait characteristics in school-age children with AS using three-dimensional gait analysis (3DGA). Patients with clinically and genetically confirmed AS and healthy children aged 6-15 years were included.

View Article and Find Full Text PDF

Clinical and Cytogenetic Impact of Maternal Balanced Double Translocation: A Familial Case of 15q11.2 Microduplication and Microdeletion Syndromes with Genetic Counselling Implications.

Genes (Basel)

November 2024

Laboratório de Citogenética Clínica, Centro de Genética Médica, Instituto Nacional da Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira-Fundação Oswaldo Cruz, Rio de Janeiro 22250-020, Brazil.

Background: Balanced chromosomal translocations occur in approximately 0.16 to 0.20% of live births.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!